Stock Scorecard
Stock Summary for KalVista Pharmaceuticals Inc (KALV) - $8.09 as of 12/20/2024 3:43:42 PM EST
Total Score
8 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KALV
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KALV
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KALV
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KALV
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for KALV (32 out of 100)
Stock Price Rating (Max of 10) | 4 |
Historical Stock Price Rating (Max of 10) | 6 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 9 |
Price to Earnings (Max of 10) | 0 |
Latest News for for KALV
Financial Details for KALV
Company Overview |
|
---|---|
Ticker | KALV |
Company Name | KalVista Pharmaceuticals Inc |
Country | USA |
Description | KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 10/31/2024 |
Next Earnings Date | 3/10/2025 |
Stock Price History |
|
Last Day Price | 8.09 |
Price 4 Years Ago | 18.99 |
Last Day Price Updated | 12/20/2024 3:43:42 PM EST |
Last Day Volume | 1,014,235 |
Average Daily Volume | 426,511 |
52-Week High | 16.88 |
52-Week Low | 7.97 |
Last Price to 52 Week Low | 1.51% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 21.25 |
Sector PE | 40.44 |
5-Year Average PE | -5.17 |
Free Cash Flow Ratio | 2.94 |
Industry Free Cash Flow Ratio | 11.59 |
Sector Free Cash Flow Ratio | 27.17 |
Current Ratio Most Recent Quarter | 6.87 |
Total Cash Per Share | 2.75 |
Book Value Per Share Most Recent Quarter | 4.86 |
Price to Book Ratio | 2.98 |
Industry Price to Book Ratio | 5.00 |
Sector Price to Book Ratio | 20.63 |
Price to Sales Ratio Twelve Trailing Months | 107.42 |
Industry Price to Sales Ratio Twelve Trailing Months | 81.68 |
Sector Price to Sales Ratio Twelve Trailing Months | 24.53 |
Analyst Buy Ratings | 5 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 49,418,000 |
Market Capitalization | 399,791,620 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -36.31% |
Reported EPS 12 Trailing Months | -3.68 |
Reported EPS Past Year | -1.78 |
Reported EPS Prior Year | -3.40 |
Net Income Twelve Trailing Months | -156,388,000 |
Net Income Past Year | -126,644,000 |
Net Income Prior Year | -92,907,000 |
Quarterly Revenue Growth YOY | 30.70% |
5-Year Revenue Growth | -38.37% |
Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 135,776,000 |
Total Cash Past Year | 210,401,000 |
Total Cash Prior Year | 149,375,000 |
Net Cash Position Most Recent Quarter | 135,776,000 |
Net Cash Position Past Year | 210,401,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 206,582,000 |
Total Stockholder Equity Prior Year | 161,025,000 |
Total Stockholder Equity Most Recent Quarter | 133,992,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -123,057,000 |
Free Cash Flow Per Share Twelve Trailing Months | -2.49 |
Free Cash Flow Past Year | -89,674,000 |
Free Cash Flow Prior Year | -76,457,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.47 |
MACD Signal | -0.44 |
20-Day Bollinger Lower Band | 8.34 |
20-Day Bollinger Middle Band | 11.14 |
20-Day Bollinger Upper Band | 13.93 |
Beta | 0.91 |
RSI | 37.92 |
50-Day SMA | 12.14 |
150-Day SMA | 10.71 |
200-Day SMA | 13.41 |
System |
|
Modified | 12/21/2024 4:13:32 AM EST |